Anti-inflammatory therapeutics market seen reaching $152 billion by 2030

By AI, Created 11:14 AM UTC, May 20, 2026, /AGP/ – The global anti-inflammatory therapeutics market is projected to grow from $122.27 billion in 2026 to $152.04 billion by 2030, driven by rising inflammatory bowel disease cases, aging populations and new biologic therapies. North America led the market in 2025, while Europe is expected to grow fastest through the forecast period.

Why it matters: - The anti-inflammatory therapeutics market is expanding as demand rises for drugs that reduce pain, inflammation and fever across acute and chronic conditions. - Growth in the market signals more spending on treatments for arthritis, inflammatory bowel disease and chronic pain. - The forecast points to sustained opportunity for drug developers, pharmacies and healthcare providers as patient need broadens.

What happened: - The Business Research Company released its Anti-Inflammatory Therapeutics Global Market Report 2026 on May 8, 2026. - The report places the market at $117.28 billion in 2025 and $122.27 billion in 2026, a 4.3% increase. - The market is projected to reach $152.04 billion by 2030, growing at a 5.6% CAGR. - North America held the largest regional share in 2025. - Europe is expected to be the fastest-growing region during the forecast period.

The details: - The report links historic growth to more arthritis cases, a surge in inflammatory bowel diseases, expansion of hospital pharmacy networks, wider corticosteroid use and higher demand for pain-management medicines. - Anti-inflammatory therapeutics are prescription drugs used to relieve pain, reduce inflammation and lower elevated body temperature. - The medications act as host response modifiers and are used for headaches, sprains, strains and other inflammatory disorders. - The report says future growth will be supported by targeted biologic therapies, artificial intelligence in drug discovery, online pharmacies, an aging global population and personalized medicine. - Expected trends include customized anti-inflammatory treatments, more biologic drug use, minimally invasive delivery methods, broader chronic pain management approaches and better access through digital pharmacy platforms. - The report covers North America, South America, Western Europe, Eastern Europe, Asia-Pacific, South East Asia, the Middle East and Africa. - The Business Research Company offers a free sample of the report and the full market report.

Between the lines: - Rising inflammatory bowel disease cases appear to be a major demand driver because anti-inflammatory drugs help control symptoms and reduce the need for surgery in Crohn’s disease. - Crohn’s and Colitis Canada projected in June 2023 that the number of people with IBD in Canada will rise to 470,000 by 2035 from about 322,600 in 2023. - The forecast suggests that biologics and digital distribution channels are moving from niche options toward more central roles in treatment access and development.

What’s next: - The market is expected to keep expanding through 2030 as more patients need long-term inflammatory disease care. - Product development is likely to focus on more precise therapies and easier delivery methods. - Regional growth may continue to shift toward Europe as the global patient base and treatment options broaden.

The bottom line: - Anti-inflammatory therapeutics remain a durable healthcare market, with growth tied to rising chronic inflammation, innovation in biologics and broader access through digital and pharmacy channels.